跳至主要内容
临床试验/NCT06281067
NCT06281067招募中不适用

Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine: RIALTO PRO

Azienda Ospedaliero Universitaria Maggiore della Carita40 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2023年12月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
500
试验地点
40
主要终点
The composite of significant angina and MACE

研究概览

简要总结

The "RIALTO-PRO" study aims to optimize the diagnostic and therapeutic algorithm for myocardial bridge (MB) patients, testing the diagnostic value of a full invasive diagnostic procedure, and, consequently, the prognostic value of a tailored approach. the study objective is to determine the diagnostic and prognostic value of a full-physiology approach strategy versus a standard approach strategy in patients with a MB.

The "RIALTO PRO" study is a randomized, multicentre, prospective, open-label, superiority trial comparing a personalised versus standard management in patients with MB. Consenting and eligible patients will be randomised 1:1 to either a "full-physiology approach", consisting of a comprehensive diagnostic algorithm aimed at unmasking the main pathophysiological mechanism of myocardial ischemia and consequently a tailored treatment, or a "standard approach", consisting of angiographic evaluation of the tunnelled segment.

详细描述

TRIAL PROCEDURES Once MB is angiographically detected, eligible and consenting patients will be randomly assigned in a 1:1 ratio to receive a "standard approach" or a "full-physiology approach" during index CA.

Index coronary angiography Coronary angiography will be performed through a radial or femoral approach. Unfractionated heparin (initial weight-adjusted intravenous bolus of 50-70 IU/kg, with repeat boluses to achieve an activated clotting time ∼250) will be administered in all patients. To fully expose all segments of the coronary arteries, at least 2 perpendicular projections for the right coronary artery (RCA) and 4 projections for the LAD will be taken. Intracoronary nitrates can be used (depending on blood pressure and, in any case, at the discretion of the Investigator) to increase the angiographic sensitivity in detecting the "milking effect".

Physiological epicardial and microvascular assessment MB hemodynamic assessment will be performed using a diagnostic guidewire placed in the index vessel. Intravenous heparin (50-70 U/kg) should be administered to achieve therapeutic anticoagulation (activated clotting time ∼250 s). The innovative Abbott PressureWire™ X Guidewire will be used to measure pressure and temperature. The guidewire's wireless measurements are connected to an advanced platform (Coroventis‡ CoroFlow‡ Cardiovascular System) to measure physiological indices. Abbott's PressureWire™ X Guidewire and Coroventis‡ CoroFlow‡ Cardiovascular System are, nowadays, the only solution for the cath lab able to assess both epicardial vessel (i.e., FFR< 0.80) and microcirculation (i.e., CFR< 2.0 and IMR≥ 25).

Epicardial assessment will include:

  • Resting Pd/Pa (n.v. > 0.92)
  • FFR after intravenous adenosine administration (n.v. > 0.80)
  • RFR (n.v. > 0.89)
  • FFR after intravenous dobutamine administration (n.v. > 0.75) FFR is defined as the mean distal pressure (Pd)/mean aortic pressure (Pa) across MB during maximal hyperemia, achieved by administration of intravenous (140 μg/kg/min) or intracoronary bolus (up to 200 µg) of adenosine. Pd/Pa was automatically calculated by current computational software as the ratio found in the pressure recording. A cut-off of 0.80 will be used to detect hemodynamic relevance. Inotropic stimulation to exalt the hemodynamic significance of MB will be performed with intravenous dobutamine infusion, in case of a negative functional assessment (Pd/Pa> 0.92, FFR> 0.80, RFR> 0.89). The infusion will be started at 5 μg/kg/min and increased by 5μg/kg/min every 5 minutes up to 20 μg/kg/min or until the patient develops symptoms or clear evidence of ischemia. An intravenous infusion of 1 mg atropine will be administered if the patient will not experience symptoms or signs of myocardial ischemia with 20 μg/kg/min of dobutamine infusion. An intravenous bolus of β-blocker (i.e., metoprolol 5 mg) will be administered at the end of the procedure to antagonize the effects of dobutamine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to give informed consent to the study.
  • Age ≥ 18 years and ≤ 75 years.
  • Diagnosis of MB during index coronary angiography*.
  • Symptoms or signs of inducible ischemia (if signs, these should involve the territory of the index vessel).
  • Angiographic definition of MB *
  • Myocardial bridge is a congenital anomaly characterized by an intramural course of an epicardial coronary segment. This anatomical arrangement causes the artery to be squeezed during systole, with a relaxation in diastole. In this study, MB is defined as a visual ≥ 50% reduction in the minimal luminal diameter during systole and a complete or partial relaxation in diastole ("milking effect").
  • The use of intracoronary vasodilators (i.e., nitrates) can increase the systolic narrowing of the vessel, through a reflex rise of the adrenergic drive, and consequently the angiographic sensitivity in detecting MB.

排除标准

  • Moderate to severe CAD (≥ 50% stenosis in any vessel, including chronic total occlusion) at the time of enrolment/randomization.
  • Previous CABG involving the index vessel.
  • Severe valvular heart disease.
  • Left ventricular systolic dysfunction [ejection fraction (EF) < 40%], regardless of the etiology.
  • Clinically significant right ventricular dysfunction.
  • Known severe renal impairment (eGFR < 30 ml/min/1.73 m2).
  • Known severe hepatic impairment, or history of cirrhosis with evidence of portal hypertension.
  • History of malignancy of any organ system with a life expectancy < 1 year.
  • Any previous history of ischemic stroke, intracranial haemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
  • Pregnant or breastfeeding women.
  • Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (nitrates, adenosine, dobutamine, acetylcholine).

结局指标

主要结局

The composite of significant angina and MACE

时间窗: at 1-year follow-up

Composite of significant anginal burden, defined as Seattle angina questionnaire (SAQ) Summary Score ≤ 70, and MACE, defined as the composite of cardiac death, myocardial infarction, cardiac hospitalization (any cause) and target vessel revascularization at 1 year follow-up.

次要结局

  • Rate of patients with significant angina (SAQ Angina Summary Score ≤ 70)(at 1-year follow-up)
  • Incidence of MACE(at 1-year follow-up)
  • Rate of TLR(at 1-year follow-up)
  • Rate of cardiac death(at 1-year follow-up)
  • Rate of MI(at 1-year follow-up)
  • Rate of cardiac hospitalization(at 1-year follow-up)

研究者

发起方
Azienda Ospedaliero Universitaria Maggiore della Carita
申办方类型
Other
责任方
Principal Investigator
主要研究者

Domenico D'Amario

Prof

Università degli Studi del Piemonte Orientale Amedeo Avogadro

研究点 (40)

Loading locations...

相似试验